Literature DB >> 30378656

Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Response to the letter of Siniorakis et al.

Maciej Liczek, Iga Panek, Piotr Damiański, Olga Jęczeń, Jędrzej Jaźwiec, Piotr Kuna, Michał Panek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30378656     DOI： 10.5603/ARM.2018.0042

Source DB:  PubMed          Journal:  Adv Respir Med        ISSN： 2451-4934


× No keyword cloud information.
  2 in total

1.  Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats.

Authors:  Shao-Jung Hsu; Hui-Chun Huang; Chiao-Lin Chuang; Ching-Chih Chang; Ming-Chih Hou; Fa-Yauh Lee; Shou-Dong Lee
Journal:  Pharmaceutics       Date:  2020-04-02       Impact factor: 6.321

2.  Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.

Authors:  Jeffrey S Tran; Ofer Havakuk; Jennifer M McLeod; Jennifer Hwang; Hoi Yan Kwong; David Shavelle; Michael R Zile; Uri Elkayam; Michael W Fong; Luanda P Grazette
Journal:  ESC Heart Fail       Date:  2021-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.